Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
110%(11 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_4
1
8%
Ph phase_2
1
8%
Ph phase_3
10
83%

Phase Distribution

0

Early Stage

1

Mid Stage

11

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
10(83.3%)
Phase 4Post-market surveillance
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(10)
Terminated(2)

Detailed Status

Completed10
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (8.3%)
Phase 310 (83.3%)
Phase 41 (8.3%)

Trials by Status

terminated18%
completed1083%
withdrawn18%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

NCT01577732
completedphase_3

Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.

NCT00609492
completedphase_3

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

NCT01309646
completedphase_3

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

NCT02858440
completedphase_4

Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment

NCT01235949
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT01577732Phase 3

Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

Completed
NCT00609492Phase 3

Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.

Completed
NCT01309646Phase 3

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

Completed
NCT02858440Phase 3

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

Completed
NCT01235949Phase 4

Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment

Completed
NCT01003418Phase 2

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Terminated
NCT01119625Phase 3

Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose

Completed
NCT00808444Phase 3

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age

Completed
NCT00307034Phase 3

Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule

Completed
NCT01086423Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

Completed
NCT00964028Phase 3

Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)

Completed
NCT03128489Phase 3

Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants

Withdrawn

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12